Devices/Warning Letter·FDA Warning Letters

Warning Letter — 3B Medical, Inc. dba Reach Health, Inc.

MediumPublished Jun 30, 2026· AI-analyzed Jun 30, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

The FDA issued a Warning Letter to 3B Medical, Inc. (doing business as Reach Health, Inc.) following an evaluation by the Center for Devices and Radiological Health.

Who it affects

This notice affects 3B Medical, Inc., its subsidiary Reach Health, Inc., and their internal departments responsible for regulatory compliance, quality management, and medical device distribution.

Why it matters

A Warning Letter from CDRH indicates that the FDA has identified significant violations of regulatory requirements. While the specific nature of the violations is not detailed in the provided excerpt, such letters typically involve issues related to Quality System Regulations (QSR), marketing unauthorized devices, or failure to follow post-market reporting requirements. This represents a heightened level of enforcement that necessitates formal remediation to avoid further legal action or seizure of products.

Practical takeaway

Regulatory and Quality teams should review all device marketing and manufacturing status to ensure that current distribution aligns with active FDA clearances and registrations. Conduct an internal audit of existing product portfolios to verify that no devices are being marketed without the necessary pre-market authorizations.

FDA source material

FDA Warning Letter issued to: 3B Medical, Inc. dba Reach Health, Inc.. 05/20/2026 — Center for Devices and Radiological Health. Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/3b-medical-inc-dba-reach-health-inc-725108-05202026

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.